Worst performer was TLOU:Tlou Energy which announced a heavily discounted placing and dropped 17%. This was a bit of a pain, but improved dramatically by the entitlement offer made to existing shareholders to top up for even less than the placing price. No message on my account yet, but hopefully the purchase option will become available soon, and I will take it up.
TND:Tandem Group decided that being Share of the Week last week meant it should drop 5% today and is back to 27% down overall. I so wish I could get rid of these!
OPTI:Optibiotix dropped 2p which was only 3% but wiped over £1,200 off my paper profits.
N4P:N4 Pharma had a good week and moved up 6% to go 6% up and in profit, albeit only £73.
SBTX:SkinBioTherapeutics had an amazing week, climbing 20% to go 27% up with paper profit of £283. My limit order is still active, but I may cancel it over the weekend as the price hasn't dropped straight back down, so there is a risk it will hang around this level. I really don't know if I can watch them drop like OPTI:Optibiotix keep doing, but I'm torn as I'm meant to be an investor not a trader, and my trading performance has been utterly terrible, as you are about to read.
Normally I would have been leaping around with joy at VRS:Versarien climbing 31% this week, but they were meant to drop to 75p after my selling 25% of my shares for 94.82p! So I was torn between celebrating my holding going up to 61% profit and £2,612 in the black, and my misery that I wasn't going to be able to get my 25% back. I'm a rubbish trader! It could have been worse - I could have sold all my shares rather than 25%. That would have been really painful. I guess it was understandable that I wouldn't trust AIM to allow a re-rate to stick. I just happened to be wrong.
This is the new chart, showing the last 12 months rather than starting from almost 3 years ago. That chart is still visible in the right-hand side-bar. I didn't realise how fast the portfolio cost has been rising recently. I've added a trend line and I'm happy to say it's pointing upwards.
The ISA and share accounts look like this
| Weekly Change | |||
| Cash | £7.38 | -£3.75 | |
| Portfolio cost | £52,236.06 | +£0 | |
| Portfolio sell value (bid price - commission) | £48,357.34 | (-7.4%) | +£223.98 |
| Potential profits | £3,054.31 | +£740.66 | |
| Yr 3 Dividends | £44.15 | +£0 | |
| Yr 3 Profit from sales | £8,387.31 | +£0 | |
| Yr 3 Average monthly cash profit | £826.68 | (19%) | -£19.60 |
| Total Dividends | £1,223.20 | +£0 | |
| Total Profit from sales | £15,099.81 | +£0 | |
| Average monthly cash profit | £473.74 | (10.9%) | -£3.34 |
| (Sold stocks profit + Dividends - Fees / Months) |
Monthly fees took some cash, and thanks to VRS:Versarien and SBTX:SkinBioTherapeutics the potential profits defied OPTI:Optibiotix and climbed £740. Deepening losses caused by multiple small drops battered £500 of that away leaving a small £223 rise.
The problem with switching to an annual graph means the gap looks even bigger. Trend line not so positive either.
The SIPP looks like this after week 132
| Weekly Change | |||
| Cash | £30.28 | -£205.26 | |
| Portfolio cost | £27,893.76 | +£281.09 | |
| Portfolio sell value (bid price - commission) | £28,848.86 | (3.4%) | -£371.10 |
| Potential profits | £2,691.06 | -£357.39 | |
| Yr 3 Dividends | £292.57 | +£87.07 | |
| Yr 3 Profit from sales | £1,619.73 | +£0 | |
| Yr 3 Average monthly cash profit | £284.60 | (12.2%) | +£1.63 |
| Total Dividends | £1,208.67 | +£87.07 | |
| Total Profit from sales | £10,544.92 | +£0 | |
| Average monthly cash profit | £378.59 | (16.3%) | -£0.38 |
| (Sold stocks profit + Dividends - Fees / Months) |
Cash dropped after dividends were re-invested today. I bought 3,741 shares in PAF:Pan African Resources for 7.1585p costing £281.09. That brings my total holding to 19,180 at a weighted average of 7.375p costing £1,445.58. They are down 5% and losing £74 so far, but that includes 2 lots of commission. Prior to the purchase I had £11 monthly charge taken out of my cash, but also added £87.07 dividend from LGEN:Legal & General. The dividend was enough to limit the drop in monthly performance to 38p. Losses from the OPTI:Optibiotix drop were limited by small rises elsewhere and the good rise from N4P:N4 Pharma.
Still in the black and a very healthy trend line. Doesn't seem like almost a year ago I sold all those IQE:IQE shares and had the big rise in portfolio cost from the re-investment.
That's it for a frustrating week. So near to being great but it all petered out into a damp squib.
No comments:
Post a Comment